176 related articles for article (PubMed ID: 30668345)
21. Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity.
Panossian A; Wikman G
Curr Clin Pharmacol; 2009 Sep; 4(3):198-219. PubMed ID: 19500070
[TBL] [Abstract][Full Text] [Related]
22. Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions.
Aslanyan G; Amroyan E; Gabrielyan E; Nylander M; Wikman G; Panossian A
Phytomedicine; 2010 Jun; 17(7):494-9. PubMed ID: 20374974
[TBL] [Abstract][Full Text] [Related]
23. Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients.
Loo WT; Jin LJ; Chow LW; Cheung MN; Wang M
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S91-100. PubMed ID: 20374035
[TBL] [Abstract][Full Text] [Related]
24. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
25. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
26. Plant Adaptogens-History and Future Perspectives.
Todorova V; Ivanov K; Delattre C; Nalbantova V; Karcheva-Bahchevanska D; Ivanova S
Nutrients; 2021 Aug; 13(8):. PubMed ID: 34445021
[TBL] [Abstract][Full Text] [Related]
27. Antioxidant evaluation of three adaptogen extracts.
Chen TS; Liou SY; Chang YL
Am J Chin Med; 2008; 36(6):1209-17. PubMed ID: 19051347
[TBL] [Abstract][Full Text] [Related]
28. Anti-Neuroinflammatory Effects of Adaptogens: A Mini-Review.
Wróbel-Biedrawa D; Podolak I
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398618
[No Abstract] [Full Text] [Related]
29. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
[TBL] [Abstract][Full Text] [Related]
30. The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections.
Panossian A; Brendler T
Pharmaceuticals (Basel); 2020 Sep; 13(9):. PubMed ID: 32911682
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
32. A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).
Lindman H; Andersson M; Ahlgren J; Balslev E; Sverrisdottir A; Holmberg SB; Bengtsson NO; Jacobsen EH; Jensen AB; Hansen J; Tuxen MK; Malmberg L; Villman K; Anderson H; Ejlertsen B; Bergh J; Blomqvist C;
Eur J Cancer; 2018 May; 94():79-86. PubMed ID: 29547834
[TBL] [Abstract][Full Text] [Related]
33. Adaptogens stimulate neuropeptide y and hsp72 expression and release in neuroglia cells.
Panossian A; Wikman G; Kaur P; Asea A
Front Neurosci; 2012; 6():6. PubMed ID: 22347152
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
[TBL] [Abstract][Full Text] [Related]
36. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.
Erselcan T; Kairemo KJ; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H
Br J Cancer; 2000 Feb; 82(4):777-81. PubMed ID: 10732745
[TBL] [Abstract][Full Text] [Related]
37. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.
Paradiso A; Schittulli F; Cellamare G; Mangia A; Marzullo F; Lorusso V; De Lena M
J Clin Oncol; 2001 Oct; 19(19):3929-37. PubMed ID: 11579113
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
Riccardi A; Pugliese P; Danova M; Brugnatelli S; Grasso D; Giordano M; Bernardo G; Giardina G; Fava S; Montanari G; Pedrotti C; Trotti G; Rinaldi E; Poli MA; Tinelli C
Br J Cancer; 2001 Jul; 85(2):141-6. PubMed ID: 11461067
[TBL] [Abstract][Full Text] [Related]
39. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
French Adjuvant Study Group
J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
[TBL] [Abstract][Full Text] [Related]
40. Aqueous extracts and polysaccharides from Marshmallow roots (Althea officinalis L.): cellular internalisation and stimulation of cell physiology of human epithelial cells in vitro.
Deters A; Zippel J; Hellenbrand N; Pappai D; Possemeyer C; Hensel A
J Ethnopharmacol; 2010 Jan; 127(1):62-9. PubMed ID: 19799989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
